Sophia Randolph

Sophia Randolph

Company: ALX Therapeutics Inc.

Job title: Chief Medical Officer

Seminars:

ALX148 a Novel CD47 Myeloid Checkpoint Inhibitor in Patients with HNSCC 2:30 pm

CD47 is an anti-phagocytic SIRPα ligand often overexpressed by cancer cells to evade immune response correlates with poor clinical prognosis. The disruption of the CD47-SIRPα anti-phagocytic signal via CD47 blockade has been shown to maximize phagocytic activity against tumor cells in combination with a pro-phagocytic signal. Targeting the CD47-SIRPα myeloid checkpoint interaction with cancer therapeutics…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.